|
RNF5P1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.10270000003499E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.97030000004261E-06 |
| Normal-vs-Stage2 |
9.52490000000195E-05 |
| Normal-vs-Stage3 |
2.96570000002383E-07 |
| Normal-vs-Stage4 |
1.164520E-04 |
| Stage1-vs-Stage2 |
3.906600E-01 |
| Stage1-vs-Stage3 |
2.541900E-02 |
| Stage1-vs-Stage4 |
4.513800E-01 |
| Stage2-vs-Stage3 |
5.262600E-01 |
| Stage2-vs-Stage4 |
9.231400E-01 |
| Stage3-vs-Stage4 |
4.463200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.7478099999968E-05 |
| Normal-vs-AfricanAmerican |
2.2417999999913E-05 |
| Normal-vs-Asian |
3.388800E-04 |
| Caucasian-vs-AfricanAmerican |
3.497400E-01 |
| Caucasian-vs-Asian |
7.722800E-01 |
| AfricanAmerican-vs-Asian |
5.143400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.79899999999778E-06 |
| Normal-vs-Female |
7.77219999470447E-08 |
| Male-vs-Female |
4.517200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.92921999999651E-05 |
| Normal-vs-Age(41-60Yrs) |
4.12510000002975E-06 |
| Normal-vs-Age(61-80Yrs) |
4.31729996197561E-09 |
| Normal-vs-Age(81-100Yrs) |
9.872100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.708400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.838100E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.768400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.380400E-04 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.646000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.154100E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.126200E-01 |
| Classical-VS-Follicular |
1.849550E-01 |
| Classical-VS-Other |
4.750200E-01 |
| Classical-VS-Normal |
1.75825999999546E-05 |
| Tall-VS-Follicular |
2.951900E-02 |
| Tall-VS-Other |
9.268800E-01 |
| Tall-VS-Normal |
4.047900E-02 |
| Follicular-VS-Other |
2.731200E-01 |
| Follicular-VS-Normal |
3.1713000003819E-07 |
| Other-VS-Normal |
2.238200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.18269999963105E-07 |
| Normal-vs-N1 |
1.43790000017852E-07 |
| N0-vs-N1 |
8.576100E-02 |
|
|
